In AD and PD, AI-driven neuroimaging and biomarker analysis allow for precisely identifying pathological changes, including amyloid plaques, tau tangles, and neural degeneration, long before the onset of clinical symptoms. This evidence concerns the gene MAPT and Parkinson disease.